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Clostridium difficile infection (CDI) is a significant 
and increasing medical problem, surpassing methicillin-
resistant Staphylococcus aureus as the most common 
hospital-onset or facility-associated infection,1-3 and a 
key element in the challenging battle against hospital-
acquired infections. This Gram-positive, anaerobic, 
spore-forming colonizes the intestinal tract after 
antibiotics have altered the normal intestinal flora. CDI 
may be life-threatening; the death rate has dramatically 
increased from 3,000 per year in 1999-2000 to 14,000 
per year in 2006-2007.4 The use of antibiotics, although 
not the only risk factor, is the most significant triggering 
event, increasing in incidence with prolonged antibiotic 
use.2,3,5 Many antibiotics have been implicated in 
the etiopathogenesis of CDI, especially ampicillin, 
amoxicillin, clindamycin, cephalosporin (particularly 
third generation cephalosporins) and quinolones.2,3,6-8 
However, not all cases of CDI are associated with 
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antibiotics or their prolonged use. In 24% of cases 
of CDI there was no history of previous use of 
antibiotics and 9% had less than 3 days of use.9 Most 
of these were hospitalized individual who had close 
contact with patients with diarrheal diseases. Other 
risk factor includes administration of antineoplastic 
agents like doxorubicin, cisplatin, cyclophosphamide, 
fluorouracil and chlorambucil, methotrexate.10 
Immunocompromised patients, either from cancer 
chemotherapy or, especially, after transplantation, 
also were prone to develop CDI. Other risk factors 
include: preceding inflammatory bowel disease (IBD) 
and other comorbidities, advanced age, enteral feeding 
(especially post pyloric), prior gastrointestinal surgery, 
and proton pump inhibitor users.2,3,11
Clinical presentation varies widely (Table 1). 
Asymptomatic (culture positive) carriers can have 
mild colitis without the characteristic inflammatory 
(“pseudo”) membrane formation or fulminant toxic 
megacolon. Watery diarrhea is a cardinal manifestation 
accompanied by cramps and lower abdominal pain. 
Acute abdomen, requiring emergency surgery, has 
been described.11,12 Symptoms generally start 2-10 days 
after antibiotic use. Although frankly bloody diarrhea is 
uncommon, occult blood is present in 26% of cases. As 
many as 50% of patients have a low-grade fever. When 
the temperature is greater than 38.5 °C there is usually 
severe disease. Leukocytosis, with increased band 
forms is frequent, as is hypoalbuminemia. Creatinine 
value elevations are seen with increasing severity of the 
diarrhea. Acute inflammatory exudate may be present 
in as many as 40% of stool samples.11,13-15 Imaging 
studies are of little use in detecting CDI and endoscopy 
is indicated when rapid diagnosis is required. Findings 
may vary: normal mucosa (in mild cases), mild erythema, 
and friability can be seen before the appearance of the 
characteristic multiple, raised and centrally ulcerated, 
yellowish-white plaques (pseudomembranes).16 The 
entire colorectal mucosa can be affected in the most 
severe cases but, most often, the lesions are patchy 
and separated by unremarkable mucosa, as in the 
image above. With effective therapy the mucosa heals 
completely.
Symptom recurrence may be due to reinfection 
by a different strain or can represent relapse with 
the original strain, and may be characterized by one 
or several episodes, starting days or weeks after 
treatment. Relapse may be more severe than the first 
episode.17
Currently, many laboratory assays have been 
used to diagnose CDI, but no single “gold standard” 
has been recognized.2,3,11 C. difficile toxin is obtained 
from stool samples, which should be maintained 
at temperature under 4 °C if not immediately 
processed since the toxin is heat sensitive (a frequent 
cause of false-negative result). For this purpose the 
available tests are: Polymerase chain reaction (PCR), 
Enzyme immunoassay (EIA) for C. difficile glutamate 
dehydrogenase (GDH), Enzyme immunoassay (EIA) for 
C. difficile toxins A and B, Cell culture cytotoxicity assay 
and selective anaerobic culture.
Histologic examination is characteristic but, in 
biopsy samples, may be indistinguishable from acute 
ischemic colitis.
Less severe CDI may be treated with oral 
metronidazole or vancomycin with 90-98% cure rates. 
As the results are considered similar, metronidazole 
has been favored over vancomycin to limit the 
spread of vancomycin-resistant enterococci. Other 
treatment choices include fidaxomicin and rifaximin. 
Recently, fecal transplantation to either the upper or 
lower gastrointestinal tract has been shown to be 
dramatically effective in many cases of severe CDI.18-20
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